MLL Legal represents Bayer HealthCare before the Federal Patent Court

The Swiss Federal Patent Court held Bayer’s patent to be preliminarily valid and – in particular – confirmed the existence of inventive step. The court granted a preliminary injunction prohibiting generic company Helvepharm from distributing its generic “Sorafenib Zentiva” in Switzerland.

Patent owner Bayer HealthCare filed a request for preliminary injunction based on the Swiss/Lichtenstein part of its European Patent against generic company Helvepharm, which belongs to the Zentiva group of companies, and its generic product “Sorafenib Zentiva” with the Swiss Federal Patent Court in October 2021.

While courts in Germany, France, the United Kingdom, Spain and the Netherlands had already found Bayer’s patent invalid for lack of inventive step, the Swiss Federal Patent Court, in line with the Vienna Commercial Court, confirmed the validity of the patent. Ordinary proceedings on the merits of the case are pending before the Swiss Federal Patent Court.

Bayer HealthCare was represented by MLL Legal. The team was lead by Simon Holzner (partner, head of the patent and life sciences team, pictured), Ulrike Ciesla (partner, European patent attorney) and Louisa Galbraith (senior associate).

MLL Legal represents Bayer HealthCare before the Federal Patent Court


Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website

LC Publishing Group S.p.A. – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 50.000,00 i.v.

Copyright 2023 © All rights Reserved. Design by Origami Creative Studio


Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram